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A B S T R A C T
Wallerian degeneration of physically injured axons involves a well-defined molecular pathway linking loss of
axonal survival factor NMNAT2 to activation of pro-degenerative protein SARM1. Manipulating the pathway
through these proteins led to the identification of non-axotomy insults causing axon degeneration by a
Wallerian-like mechanism, including several involving mitochondrial impairment. Mitochondrial dysfunction is
heavily implicated in Parkinson's disease, Charcot-Marie-Tooth disease, hereditary spastic paraplegia and other
axonal disorders. However, whether and how mitochondrial impairment activates Wallerian degeneration has
remained unclear. Here, we show that disruption of mitochondrial membrane potential leads to axonal NMNAT2
depletion in mouse sympathetic neurons, increasing the substrate-to-product ratio (NMN/NAD) of this NAD-
synthesising enzyme, a metabolic fingerprint of Wallerian degeneration. The mechanism appears to involve both
impaired NMNAT2 synthesis and reduced axonal transport. Expression of WLDS and Sarm1 deletion both protect
axons after mitochondrial uncoupling. Blocking the pathway also confers neuroprotection and increases the
lifespan of flies with Pink1 loss-of-function mutation, which causes severe mitochondrial defects. These data
indicate that mitochondrial impairment replicates all the major steps of Wallerian degeneration, placing it
upstream of NMNAT2 loss, with the potential to contribute to axon pathology in mitochondrial disorders.
1. Introduction
Studies of axon degeneration following axotomy (Wallerian degen-
eration) and of the axon-protective protein WLDS have led to the dis-
covery of critical endogenous regulators of the mechanisms resulting in
axon degeneration (Conforti et al., 2014; Gerdts et al., 2016; Llobet
Rosell and Neukomm, 2019). The current model predicts that the
pathway regulating Wallerian degeneration (Wallerian pathway) is
activated by the loss in the axon of the labile nicotinamide mono-
nucleotide adenylyl-transferase 2 (NMNAT2), a nicotinamide adenine
dinucleotide (NAD)-synthesising enzyme. Axonal NMNAT2 levels de-
cline within a few hours when its transport and/or synthesis are im-
paired (Gilley and Coleman, 2010). Downstream of NMNAT2 depletion,
the pro-degenerative protein sterile alpha and TIR motif-containing
protein 1 (SARM1) executes the degeneration program (Osterloh et al.,
2012; Gilley et al., 2015; Gerdts et al., 2015; Loreto et al., 2015). To
date, expression of WLDS/NMNATs (which substitute for endogenous
NMNAT2 loss) and SARM1 depletion are the most effective means to
block the Wallerian pathway and preserve axons in mammals. There is
still debate about how NMNAT2 loss leads to SARM1 activation but the
rise in its substrate, NMN, appears to be important (Di Stefano et al.,
2015, 2017; Loreto et al., 2015; Cohen, 2017; Zhao et al., 2019) as well
as the fall in its product, NAD (Gerdts et al., 2015; Sasaki et al., 2016;
Essuman et al., 2017).
Most studies on the Wallerian pathway have used a physical injury
model, but there is clear evidence that related degenerative mechan-
isms can be activated by many non-injury stresses (Conforti et al.,
2014). However, the vast majority of non-axotomy models were
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performed when a more comprehensive understanding of the Wallerian
pathway was lacking and were mostly identified as being Wallerian-like
by targeting just a single step in the pathway (either by expressing of
WLDS/NMNATs or, more recently, by Sarm1 deletion). Both WLDs and
SARM1 have the potential to influence other cellular mechanisms, such
as nuclear NAD synthesis and innate immunity, respectively, so in-
volvement of the Wallerian pathway is best supported by multiple lines
of evidence.
The link between mitochondria and the Wallerian pathway is par-
ticularly intriguing. Mitochondrial dysfunction is a common theme in a
wide group of neurodegenerative disorders in which axon degeneration
is central, including Parkinson's disease (PD), Charcot-Marie-Tooth
disease, hereditary spastic paraplegia and Friedrich's ataxia (Court and
Coleman, 2012). We and others have previously shown that mi-
tochondria contribute to the later stages of Wallerian degeneration,
where the axotomy itself activates the Wallerian pathway (Barrientos
et al., 2011; Loreto et al., 2015). However, mitochondrial depolarisa-
tion, caused by the mitochondrial uncoupler Carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), also leads to degeneration of unin-
jured axons (Loreto et al., 2015), which is rescued by Sarm1 deletion
(Summers et al., 2014). Additional studies, both in vitro and in vivo, link
the Wallerian pathway to mitochondrial impairment. WldS mice are
protected against nigrostriatal axon degeneration after intraperitoneal
administration of the mitochondrial complex-1 inhibitor 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Hasbani and O'Malley,
2006). WLDS also preserves neurites and promotes neuronal survival in
primary dopaminergic neurons treated with MPP+ (the active meta-
bolite of MPTP) (Antenor-Dorsey and O'Malley, 2012). Finally,
NMNATs overexpression and Sarm1 deletion in sensory neurons delay
axon degeneration caused by rotenone, another mitochondrial com-
plex-1 inhibitor, in sensory neurons (Press and Milbrandt, 2008;
Summers et al., 2014). Thus, we hypothesised that mitochondrial im-
pairment can also act as an upstream cause, equivalent to physical in-
jury, in initiating the Wallerian pathway.
Here we combine multiple lines of evidence to firmly establish a role
for the Wallerian pathway in axon degeneration caused by mitochon-
drial depolarisation in the absence of a physical injury. We also cor-
roborate these findings using an in vivo genetic model of mitochondrial
dysfunction, reporting a neuroprotective role of regulators of Wallerian
degeneration in dopaminergic neuron loss in Pink1 mutant flies.
2. Material and methods
All studies conformed to the institution's ethical requirements in
accordance with the 1986 Animals (Scientific Procedures) Act.
2.1. Primary neuronal cultures
C57BL/6 J or CD1 (referred to as wild-type, Charles River, UK),
WldS, Nmnat2+/+, Nmnat2+/gtE, Nmnat2gtBay/gtE and Sarm1−/− mouse
SCG explants were dissected from P0–2 pups. Explants were cultured in
35 mm tissue culture dishes pre-coated with poly-L-lysine (20 μg/ml for
1 h; Sigma) and laminin (20 μg/ml for 1 h; Sigma) in Dulbecco's
Modified Eagle's Medium (DMEM, Gibco) with 1% penicillin/strepto-
mycin, 100 ng/ml 7S or 50 ng/ml 2.5S NGF (all Invitrogen) and 2% B27
(Gibco). 4 μM aphidicolin (Merck) was used to reduce proliferation and
viability of small numbers of non-neuronal cells. For cultures of dis-
sociated SCG neurons, wild-type SCG explants were incubated in
0.025% trypsin (Sigma) in PBS (without CaCl2 and MgCl2) (Sigma) for
30 min followed by incubation with 0.2% collagenase type II (Gibco) in
PBS for 20 min. Ganglia were then gently dissociated using a pipette.
Dissociated neurons were plated in a poly-L-lysine and laminin-coated
area of ibidi μ-dishes (Thistle Scientific) for microinjection experiments.
Dissociated cultures were maintained as explant cultures except that
B27 was replaced with 10% fetal bovine serum (Sigma). Culture media
was replenished every 3 days. Neurites were allowed to extend for
7 days before performing the experiments.
2.2. Drug treatments
Uncut SCG neurons were treated with CCCP or vehicle (DMSO) just
prior to imaging (time 0 h). Unless specified, FK866 (kind gift of Prof.
Armando Genazzani, University of Novara) and NMN (Sigma) were
added at the same time as CCCP. The incubation time and the drug
concentration used for every experiment are indicated in the figures
and/or figure legends.
2.3. Acquisition of phase contrast images and quantification of axon
degeneration
Phase contrast images were acquired on a DMi8 upright fluores-
cence microscope (Leica microsystems) coupled to a monochrome di-
gital camera (Hammamatsu C4742–95) or on a Zeiss TIRF microscope
coupled to an EMCCD (Photometrics PVCam) camera using Axiovision
software (Carl Zeiss Inc.). The objectives used were HCXPL 20×/0.40
Corr and Zeiss EC Plan Neofluar 20×/0.5 NA. The axon degeneration
index (Sasaki et al., 2009) was determined using an ImageJ plugin
(http://rsb.info.nih.gov/ij/download.html) which calculates the ratio
of fragmented axon area over total axon area after binarization of the
pictures and subtraction of the background.
2.4. Determination of ATP levels
For measurement of ATP levels, dissociated SCG neurons were
plated in 96-well plates at the same density. ATP measurements were
performed with the ATPlite Luminescence Assay System (PerkinElmer).
Two technical repeats were performed per each condition for every
experiment. Data are expressed as % relative to DMSO control.
2.5. Western blot
Following treatment with CCCP, SCG ganglia were separated from
their neurites with a scalpel. Neurites originating from 15 ganglia were
collected per condition, washed in ice-cold PBS containing protease
inhibitors (Sigma), and lysed directly in 15 μl 2× Laemmli buffer
containing 10% 2-Mercaptoethanol (Sigma). The remaining 15 ganglia
were also collected and lysed. For NMNAT2 immunoblots, 14 μl of
protein samples were loaded on a 12% SDS polyacrylamide gel. For
SCG10 and NAMPT immunoblots, 1:15 dilutions of the original samples
were loaded on a 12% SDS polyacrylamide gel. Membranes were
blocked for 3 h in 5% milk in TBS (50 mM Trizma base and 150 mM
NaCl, PH 8.3, both Sigma) plus 0.05% Tween-20 (Sigma) (TBST), in-
cubated overnight with primary antibody in 5% milk in TBST at 4 °C
and subsequently washed in TBST and incubated for 1 h at room tem-
perature with HRP-linked secondary antibody (Bio-Rad) in 5% milk in
TBST. Membranes were washed, treated with ECL (Enhanced
Chemiluminescence detection kit; Thermofisher) and imaged with
Uvitec Alliance imaging system. The following primary antibodies were
used: mouse anti-NMNAT2 (WH0023057M1 Sigma, 2 μg/ml), mouse
anti-NAMPT (clone OMNI 379, Cayman Chemical Company, 1:2000)
and rabbit anti-SCG10 (10586–1-AP Proteintech, 1:3000). Mouse anti
β-actin was used as a loading control (A5316 Sigma, 1:5000).
Quantification of band intensity was determined by densitometry using
ImageJ.
2.6. NMNAT2 axonal transport
Dissociated SCG neurons were microinjected using a Zeiss Axiovert
S100 microscope with an Eppendorf FemtoJet microinjector and
Eppendorf TransferMan® micromanipulator. Plasmids were diluted in
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0.5× PBS (without CaCl2 and MgCl2) and filtered using a Spin-X filter
(Costar). The mix was injected directly into the nuclei of SCG neurons
using Eppendorf Femtotips. Approximately 100 neurons were injected
per dish. Injected plasmids were allowed to express for 16 h before
CCCP treatment. Plasmids were injected at the following concentra-
tions: 30 ng/μl NMNAT2-EGFP, 30 ng/μl pDsRed2-N1. Time-lapse
imaging of axonal transport was performed on an Olympus IX70 ima-
ging system with 100×/1.35 Oil objective. During imaging, cell cul-
tures were maintained at 37 °C and 5% CO2 in an environment
chamber. Images were captured at 4 frames per sec for 2 min. Three
neurites per condition were imaged in every individual experiment.
2.7. Determination of NMN and NAD levels
Following treatment with CCCP, Sarm1−/− SCG ganglia were se-
parated from their neurites with a scalpel. Neurites and cell bodies were
washed in ice-cold PBS and rapidly frozen in dry ice and stored at
−80 °C until processed for measuring NMN and NAD. Briefly, pyridine
and adenine nucleotides were extracted by sonication in HClO4 in the
presence of cAMP (as internal standard) and subsequently analysed by
ion pair C18-HPLC chromatography and by spectrofluorometric HPLC
analysis after derivatization with acetophenone (Mori et al., 2014). The
levels of NMN and NAD were normalised to protein levels.
2.8. Drosophila experiments
Newly enclosed flies were collected daily and separated by sex into
vials of 20–35 flies for aging and experimental use. Genotypes used are
w1118 (wild-type), Pink1B9, HiwΔN and HiwΔN Pink1B9. All flies were
maintained at a constant 25 °C temperature and humidity, in plastic
vials with standard agar/cornmeal/yeast feed. Flies were exposed to a
12 h light-dark cycle. All experiments were conducted on male flies. For
PPL1 dopaminergic neuron staining, fly brains were dissected in cold
1× PBS and fixed in 4% paraformaldehyde-PBS (Sigma) for 30 min.
Samples were washed in 1× PBS with 0.3% Triton X-100 (Sigma) and
blocked for 1 h at room temperature in 1× PBS with 0.3% Trition X-
100 and 1% BSA (Sigma). Brains were incubated in primary antibody
for 72 h. After washing and incubation in a fluorescent secondary an-
tibody solution for 4 h, samples were mounted between two coverslips
in ProLong diamond antifade mountant (ThermoFisher). Confocal
images were acquired on a Leica microscopy system and blinded for
analysis. Antibodies used were mouse anti-Tyrosine Hydroxylase 1:100
(22941, Immunostar Inc.) and secondary anti-mouse IgG (H + L) Alexa
Fluor 488 (A11034, ThermoFisher). Flight assay was performed as
previously described (Agrawal and Hasan, 2015). Briefly, flies were
anaesthetised on ice for 5 min; the flat of a 30G 1″ needle (Sigma) was
attached to the anterior notum of a fly just posterior to the neck using
clear nail varnish, leaving flight muscles unimpeded. Flies were given
15 min to recover. Needles were fixed in place under a video micro-
scope. If required, a gentle mouth-blown puff of air was used to sti-
mulate flight and the flying time was recorded for 30 s. This was re-
peated 3 times per fly and the average of time spent in flight was
calculated for each condition. For climbing assays, flies were gently
transferred to fresh empty polystyrene vials without anaesthesia with a
maximum density of 25 flies per vial. Groups of up to 6 vials were
inserted into the RING device and after 5 min for the flies to adjust to
the environmental change the device was tapped three times to settle
flies to the bottom of the vials. 5 s after the last tap, a picture was taken
to assess the height climbed. Maximum height achieved was graded
into 5 mm intervals, flies that climbed< 5 cm were scored zero, and
any fly that exceeded 5 cm was awarded the maximum score. This was
repeated 3 times at 60 s intervals and an average score given for that
vial.
2.9. Statistical analysis
Appropriate statistical testing of data was performed using Prism
(GraphPad Software, La Jolla, USA). ANOVA with Tukey's, Sidak's or
Bonferroni's post hoc correction (as applicable), and log-rank (Mantel-
Cox) test were used in this study. The n numbers in each individual
experiment and the tests used are described in the figure legends. A p
value< 0.05 was considered significant (****, p < 0.0001; ***,
p < 0.001; **, p < 0.01; *, p < 0.05; NS, non-significant).
3. Results
3.1. Multiple regulators of the Wallerian pathway rescue axon degeneration
caused by mitochondrial depolarisation
The mitochondrial uncoupler CCCP is widely used to trigger mi-
tochondrial depolarisation and assess the effects of mitochondrial im-
pairment on cellular viability (Ly et al., 2003). Previous work by us and
others demonstrated that sympathetic and sensory primary neurons
exposed to CCCP undergo disruption of mitochondrial membrane po-
tential and axon degeneration (Summers et al., 2014; Loreto et al.,
2015), providing a good experimental model to study mitochondrial
dysfunction leading to axon degeneration.
A dose-response experiment in superior cervical ganglion (SCG)
neurons confirmed previous observations and allowed us to determine
the most appropriate concentration of CCCP to use across the study.
50 μM CCCP induces full mitochondrial depolarization within minutes
after its addition (Loreto et al., 2015) and a dramatic depletion of ATP
levels within the first 2 h (Fig. 1A). Importantly, it consistently pro-
moted neurite degeneration when measured at 24 h post-application
(Fig. 1B–G).
We then tested whether this degenerative process could be rescued
by regulators of the Wallerian pathway. Consistent with previous stu-
dies (Summers et al., 2014), we found that Sarm1−/− SCG neurites
were strongly protected against CCCP toxicity (Fig. 1D,E). WLDS ex-
pression was highly protective too at this concentration (Fig. 1F,G).
Our findings demonstrate that the degeneration of axons following
mitochondrial depolarisation can be delayed by multiple regulators of
the Wallerian pathway.
3.2. Mitochondrial depolarisation leads to depletion of axonal NMNAT2
NMNAT2 depletion in axons has been proposed as an initial step
that triggers the activation of the Wallerian pathway (Gilley and
Coleman, 2010; Gilley et al., 2015; Loreto et al., 2015; Walker et al.,
2017). We therefore tested whether CCCP treatment led to NMNAT2
depletion in neurites (which were uninjured until immediately prior to
harvesting separately from their cell bodies) and found that levels of
this protein in neurites rapidly decline from 2 h after CCCP addition
(Fig. 2A,B). Loss of NMNAT2 occurred before any visible morphological
damage to neurites (Fig. 2C), also confirmed by the absence of changes
to β-actin levels (Fig. 2A).
We have recently reported that lowering the expression of NMNAT2
increases axonal vulnerability to several stresses (Gilley et al., 2019). To
test whether lowering NMNAT2 expression impairs the ability to
withstand mitochondrial impairment, SCG neurons from mice with
around 60% (Nmnat2+/gtE) and 30% (Nmnat2gtBay/gtE) of wild type
Nmnat2 mRNA levels in whole brain (Gilley et al., 2019) were exposed
to CCCP. We found a significant acceleration of the degeneration pro-
cess compared to wild type neurons, with clear morphological damage
appearing as early as 4 h in Nmnat2gtBay/gtE neurites (Fig. 2D,E).
These data suggest that mitochondrial uncoupling activates the
Wallerian pathway at an early step and, together with the protection
afforded by WLDS (Fig. 1F,G), they indicate that axonal NMNAT levels
modulate axon survival after mitochondrial depolarisation.
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3.3. NMNAT2 depletion reflects impairment of both axonal transport and
synthesis
We next investigated the cause of NMNAT2 depletion after CCCP
treatment. Being a labile protein with a half-life of less than an hour
(Milde et al., 2013), any cellular process that impairs its replenishment
in axons would lead to a rapid decrease in axonal levels. Two potential
mechanisms are a deficiency in axonal transport and/or altered
synthesis, both of which are ATP-dependent. The finding that NMNAT2
levels also declined in the cell body/ganglia fraction after 4–8 h of
(caption on next page)
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CCCP addition (Fig. 3A,B) suggests that synthesis of the protein is im-
paired (although enhanced protein degradation cannot be ruled out).
However, the NMNAT2 decrease in the cell body fraction was much less
marked than that in neurites (Fig. 2A,B), suggesting that impaired
protein synthesis is not the only mechanism contributing to the de-
pletion in the neurites.
We next explored whether CCCP alters NMNAT2 axonal transport.
We microinjected GFP-tagged NMNAT2 and followed changes in its
axonal transport parameters. We found a significant reduction of the
percentage of motile NMNAT2 vesicles at 4 and 8 h after CCCP addition
(Fig. 3C,D). This may also explain the slight recovery of NMNAT2 levels
in cell bodies at 8 h after CCCP addition following the decline at 4 h
(Fig. 3A,B), as any NMNAT2 that is synthesised would be less efficiently
transported into neurites and would accumulate in cell bodies instead.
The overall reduction in axonal transport of NMNAT2 appeared to be a
result of a combination of impaired anterograde, retrograde and
Fig. 1. Regulators of the Wallerian pathway rescue axon degeneration caused by mitochondrial depolarisation.
(A) ATP levels in wild-type SCG dissociated cultures after treatment with CCCP. Data are normalised to DMSO control at each time point (Mean ± SEM; n = 4; two-
way ANOVA followed by Sidak post-hoc test; ****, p < 0.0001). (B) Representative phase contrast images of neurites from wild-type SCG explant cultures treated
with increasing concentrations of CCCP. (C) Quantification of the degeneration index in experiments described in (B) from 3 fields per sample in 2 independent
experiments (Mean ± SEM; n = 2). (D) Representative phase contrast images of neurites from wild-type and Sarm1−/− SCG explant cultures at the indicated time
points after CCCP treatment. (E) Quantification of the degeneration index in experiments described in (D) from 3 fields per sample in 4 independent experiments
(Mean ± SEM; n = 4; two-way ANOVA followed by Tukey post-hoc test; ****, p < 0.0001. Statistical significance shown relative to +50 μM CCCP). (F)
Representative phase contrast images of neurites from wild-type andWlds SCG explant cultures at the indicated time points after CCCP treatment. (G) Quantification
of the degeneration index in experiments described in (F) from 3 fields per sample in 4 independent experiments (Mean ± SEM; n = 4; two-way ANOVA followed by
Tukey post-hoc test; ****, p < 0.0001. Statistical significance shown relative to +50 μM CCCP).
Fig. 2. Mitochondrial depolarisation leads to depletion of axonal NMNAT2.
(A) Representative immunoblots of wild-type SCG neurite extracts probed for NMNAT2 and β-actin (loading control) at the indicated time points after CCCP
treatment. (B) Quantification of normalised NMNAT2 levels (to β-actin) is shown, with data presented relative to DMSO control (Mean ± SEM; n = 3; one-way
ANOVA followed by Bonferroni post-hoc test; ***, p < 0.001; **, p < 0.01). (C) Representative phase contrast images showing morphologically intact neurites at
the time points used in (A). (D) Representative phase contrast images of neurites from wild-type-Nmnat2+/+, Nmnat2+/gtE (~60% expression), Nmnat2gtBay/gtE
(~30% expression) SCG explant cultures at the indicated time points after CCCP treatment. (E) Quantification of the degeneration index in experiments described in
(D) from 3 fields per sample in 4 independent experiments (Mean ± SEM; n = 4; two-way ANOVA followed by Tukey post-hoc test; ****, p < 0.0001; ***,
p < 0.001; **, p < 0.01. Statistical significance shown relative to Nmnat2+/+ +50 μM CCCP).
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bidirectional transport, although separately none of the individual
parameters reached statistical significance (Fig. 3E). Impairment of
axonal transport following CCCP is unlikely to be specific for NMNAT2.
For instance, levels of SCG10 in neurites, another short-lived protein
involved in Wallerian degeneration (Shin et al., 2012) and sporadic ALS
(Melamed et al., 2019), also declined following CCCP administration
(Fig. S1A-D). However, as it is the case when delivery of all proteins is
impaired by axotomy, our data suggest that NMNAT2 is the limiting
factor for axonal survival following CCCP-mediated mitochondrial de-
polarisation.
Fig. 3. NMNAT2 depletion reflects impairment of both axonal transport and synthesis.
(A) Representative immunoblot of wild-type SCG cell bodies/ganglia extracts probed for NMNAT2 and β-actin (loading control) at the indicated time points after
CCCP treatment. (B) Quantification of normalised NMNAT2 levels (to β-actin) is shown, with data presented relative to DMSO control (Mean ± SEM; n = 4; one-
way ANOVA followed by Bonferroni post-hoc test; ****, p < 0.0001; **, p < 0.01; *, p < 0.05). (C) Representative kymographs of wild-type SCG dissociated
cultures expressing NMNAT2-EGFP. (D) Quantification of the % of motile NMNAT2 at the indicated time points after CCCP treatment from 3 neurites per condition in
4 independent experiments (Mean ± SEM; n = 4; two-way ANOVA followed by Sidak post-hoc test; *, p < 0.05. NS, non-significant). (E) Quantification of the % of
motile bidirectional, anterograde and retrograde NMNAT2 at the indicated time points after CCCP treatment from 3 neurites per condition in 4 independent
experiments (Mean ± SEM; n = 4; two-way ANOVA followed by Sidak post-hoc test; NS, non-significant).
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Thus, impaired axonal transport of NMNAT2 and reduced synthesis
combine to reduce axonal NMNAT2 levels after CCCP treatment. It is
possible that additional mechanisms, including impairment of local
translation in neurites and increased protein degradation could further
contribute the observed depletion.
3.4. Changes in the NMN/NAD ratio following CCCP administration
We have shown that NMNAT2 depletion leads to accumulation of its
substrate, NMN, which we suggest promotes axon degeneration (Di
Stefano et al., 2015, 2017; Loreto et al., 2015), as well as to NAD
depletion, which also plays an important role (Sasaki et al., 2016;
Essuman et al., 2017) (Fig. 4A). Thus, changes in NMN/NAD ratio is an
additional indicator of Wallerian pathway activation. We previously
reported a marked increase of NMN levels in injured sciatic nerves in
vivo (Di Stefano et al., 2015, 2017). Sasaki and colleagues recently
showed a transient increase in NMN levels in sensory neurons after
axotomy also in vitro (Sasaki et al., 2016). However, selecting the cor-
rect time points is difficult due to the substantial cellular material re-
quired for the analysis and the rapid degeneration process which
compromises the integrity of the plasma membrane, making any mea-
surement unreliable. We therefore tested whether NMN accumulates
Fig. 4. Changes in the NMN/NAD ratio following
CCCP administration.
(A) Schematic representation of NAD salvage
pathway from nicotinamide and points at which
FK866 and bacterial NMN deamidase will act (NAM,
nicotinamide; NaMN, nicotinic acid mononucleotide;
NMN, nicotinamide mononucleotide; NAD, nicoti-
namide adenine dinucleotide; NAMPT, nicotinamide
phosphoribosyltransferase; NMNAT, nicotinamide
mononucleotide adenylyltransferase). (B,C) NMN
and NAD levels and NMN/NAD ratios in neurite (B)
and cell body/ganglia (C) fractions from Sarm1−/−
SCG explant cultures at the indicated time points
after CCCP treatment (Mean ± SEM; n = 5; one-
way ANOVA followed by Bonferroni post-hoc test;
****, p < 0.0001; **, p < 0.01; *, p < 0.05.
Statistical significance shown relative to 12 h
DMSO).
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and NAD declines following mitochondrial depolarisation in Sarm1−/−
SCG neurons, where the degeneration process following CCCP admin-
istration is strongly delayed (Fig. 1D,E). We looked at 12 h after CCCP
treatment, when wild-type neurites showed the first signs of degen-
eration (Fig. 2D,E), reasoning that an increase in NMN levels should
have already occurred. We found a 2-fold increase in NMN levels and a
more modest decrease in NAD levels in neurites resulting in a robust
increase in the NMN/NAD ratio (Fig. 4B) (Fig. S2A), consistent with the
predicted effects of NMNAT2 loss. In contrast, changes in the cell bodies
were much more modest (Fig. 4C) (Fig. S2B), consistent with levels of
NMNAT2 in the soma being less affected after CCCP administration
(Fig. 3A,B) and with the presence of nuclear NMNAT1, which will
contribute to NMN and NAD homeostasis in this compartment.
Several lines of evidence suggest that NMN accumulation is not
simply a marker but is a trigger of axon degeneration. Blocking NMN
accumulation with FK866, an inhibitor of the NMN-synthesising en-
zyme NAMPT (Fig. 4A), delays Wallerian degeneration. Exogenous
administration of NMN restores its accumulation in the presence of
FK866, reverting the protection (Di Stefano et al., 2015; Loreto et al.,
2015). Also scavenging NMN with expression of bacterial enzyme NMN
deamidase, which converts NMN into NaMN (Fig. 4A), results in strong
protection of injured axons in mouse primary neurons and in vivo in
mice and zebrafish (Di Stefano et al., 2015, 2017; Loreto et al., 2015).
We therefore tested whether NMN accumulation also promotes axon
degeneration after CCCP administration. We first confirmed that the
levels of NAMPT were not affected by CCCP treatment (Fig. 5A,B). This
is important since NAMPT expression is required for NMN synthesis,
which results in the accumulation of NMN in the absence of NMNAT2.
We then tested whether blocking NMN synthesis with FK866 delays
CCCP-induced axon degeneration. As with axon degeneration after
axotomy (Di Stefano et al., 2015), FK866 treatment strongly delayed
neurite degeneration following CCCP administration. Of note, co-ad-
ministration of exogenous NMN reverted FK866-induced protection
(Fig. 5C,D). In contrast to our previous findings (Di Stefano et al.,
2015), some studies reported a protective effect of NMN against ax-
otomy-induced axon degeneration (Sasaki et al., 2006), possibly due to
differences in incubation time of NMN before transection. Importantly,
we confirmed that NMN had no protective effect on the degeneration
process when added together with CCCP (Fig. 5E,F). NMNAT2 deple-
tion still occurred in neurites protected by FK866, consistent with its
expected protective action downstream of NMNAT2 loss in this situa-
tion (Fig. S3A,B) (Di Stefano et al., 2015). FK866 conferred full pro-
tection also when added up to 8 h after CCCP addition (when NMNAT2
levels in neurites are already dramatically reduced) and halted the
progression of the degeneration when added 12 h after CCCP (when
neurites appear already damaged) (Fig. S3C,D). This suggests that ac-
tivation of the pathway might be reversible, or at least the existence of a
time window after mitochondrial dysfunction when it can be prevented,
which is important in the context of therapeutic intervention in human
diseases.
Taken together, these data further support a pro-degenerative role
of NMN and are an additional confirmation that CCCP causes axon
degeneration through the activation of the Wallerian pathway.
3.5. Highwire deficiency rescues loss of a subpopulation of dopaminergic
(PPL1) neurons in Pink1 Drosophila mutants
To validate our findings in an in vivo model where mitochondrial
dysfunction is caused by a genetic mutation, we employed a Drosophila
mutant with a loss-of-function mutation in the PD-associated gene
Pink1 (Pink1B9). Pink1 is involved in mitochondrial quality control and
mutations in this protein are linked to early-onset recessive PD (Valente
et al., 2001, 2004; Pickrell and Youle, 2015). Loss of Pink1 in flies leads
to severe mitochondrial defects resulting in, among other phenotypes,
loss of dopaminergic neurons (in the PPL1 cluster), locomotor deficits
and reduced lifespan (Clark et al., 2006; Park et al., 2006; Tain et al.,
2009; Hewitt and Whitworth, 2017). The Wallerian pathway is evolu-
tionary conserved, with several orthologous genes controlling axon
degeneration both in mammals and flies (Freeman, 2014) (Fig. S4). As
ubiquitous dSarm deletion is lethal in Drosophila, we instead opted to
assess the effects of Highwire mutation on the Pink1B9 phenotype.
Highwire, and its mammalian ortholog PHR1, are E3 ubiquitin ligases
that target Drosophila NMNAT (dNMNAT) and NMNAT2, respectively,
for proteasomal degradation and Highwire/PHR1 depletion appears to
delay axon degeneration after axotomy by increasing levels and/or
stabilising dNMNAT/NMNAT2, preventing the activation of the Wal-
lerian pathway at an early step (Xiong et al., 2012; Babetto et al., 2013)
(Fig. S4).
We first tested whether Highwire deficiency (HiwΔN) could rescue
the loss of dopaminergic neurons in the PPL1 cluster (Fig. 6A) in
Pink1B9 flies. As Highwire mutants display synaptic overgrowth during
development at the neuromuscular junction (Wan et al., 2000), we first
confirmed that the number of dopaminergic neurons in the PPL1 cluster
did not differ from wild-type flies (Fig. 6B,C). Importantly, Highwire
deletion rescued the loss of dopaminergic neurons in the PPL1 cluster
(Fig. 6B,C). Highwire deletion also significantly prolonged the lifespan
of Pink1B9 flies (Fig. 6D), but was not sufficient to rescue climbing and
flying ability (Fig. 6E,F), likely due to the widespread muscle degen-
eration that is also seen in Pink1B9 flies (Clark et al., 2006; Tain et al.,
2009). Modulation of the Wallerian pathway thus appears to be pro-
tective against neurodegeneration caused by non-toxin models of mi-
tochondrial disruption in flies.
4. Discussion
The data presented here indicate that acute mitochondrial depo-
larisation by CCCP leads to axon death in the absence of a physical
injury through the same pathway that regulates Wallerian degenera-
tion. It does so by impairing axonal transport and synthesis (or stimu-
lating degradation) of the axonal survival enzyme NMNAT2, leading to
substantially reduced levels in neurites which increase the NMN/NAD
ratio and trigger SARM1-dependent axon degeneration. In addition,
neuroprotection of dopaminergic neurons conferred by Highwire dele-
tion in flies carrying mutant Pink1 suggests a wider relevance of the
Wallerian pathway to different types of mitochondrial insults in vivo.
Our previous work and that of others suggest a minor contribution
of mitochondria to the late stages of Wallerian degeneration after axon
transection (Kitay et al., 2013; Loreto et al., 2015), mainly through the
opening of mitochondria permeability transition pore and release of
Ca2+ into the cytoplasm (Barrientos et al., 2011; Villegas et al., 2014).
We now show that mitochondrial dysfunction can impact on the Wal-
lerian pathway in a second way, activating it at an early step upstream
of NMNAT2. Crucially, like FK866-protected axons (Loreto et al.,
2015), Sarm1−/− and WldS axons can be kept morphologically intact
for days despite fully depolarised mitochondria (this study and
(Summers et al., 2014; Loreto et al., 2015)). This indicates that WLDS
expression and SARM1 deficiency confer protection downstream of
mitochondrial impairment (Fig. 7), rather than directly impacting on
mitochondrial health.
The relevance of the Wallerian pathway beyond its role after ax-
otomy is now widely accepted and mitochondrial depolarisation can
now be added to a growing list of non-axotomy insults causing
Wallerian-like degeneration, including toxicity caused by che-
motherapy agents, chemicals disruption of the nigrostriatal pathway,
protein synthesis inhibition and NGF withdrawal (Conforti et al., 2014).
Importantly, most of these studies used either WLDS expression or
Sarm1 deletion as means to assess the involvement of Wallerian-like
degeneration. However, these proteins are likely to have additional,
non-Wallerian pathway functions and could thus confer a protective
phenotype independently of the Wallerian pathway. For example,
WLDS protection against neuropathy and retinopathy in a streptozo-
tocin-induced mouse model of diabetes is linked to a rescue of
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pancreatic islets (Zhu et al., 2011), likely through a mechanism that is
unrelated to its role in axons. Recent steps forward in the understanding
of the molecular mechanisms of axon degeneration revealed a well-
defined pathway of axon death, with the identification of crucial me-
chanistic links between NMNAT2 and SARM1 (Gilley et al., 2015,
2017). The knowledge of a core mechanistic pathway allows multiple
Fig. 5. Inhibition of NMN synthesis protects neurites against CCCP toxicity.
(A,B) Representative immunoblot of wild-type SCG neurite extracts probed for NAMPT and β-actin (loading control) at the indicated time points after CCCP
treatment. Quantification of normalised NAMPT levels (to β-actin) is shown, with data presented relative to DMSO control (Mean ± SEM; n = 4; one-way ANOVA
followed by Bonferroni post-hoc test; NS, non-significant). (C) Representative phase contrast images of neurites from wild-type SCG explant cultures at the indicated
time points after CCCP, FK866 and NMN treatment. Where indicated, FK866 and NMN were added at the same time of CCCP. (D) Quantification of the degeneration
index in experiments described in (C) from 3 fields per sample in 4 independent experiments (Mean ± SEM; n = 4; two-way ANOVA followed by Tukey post-hoc
test; ****, p < 0.0001. Statistical significance shown relative to +50 μM CCCP). (E) Representative phase contrast images of neurites from wild-type SCG explant
cultures at the indicated time points after CCCP and NMN treatment. (F) Quantification of the degeneration index in experiments described in (E) from 3 fields per
sample in 4 independent experiments (Mean ± SEM; n = 4; two-way ANOVA followed by Tukey post-hoc test).
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stages to be probed when seeking to establish a role for the Wallerian
pathway in non-axotomy insults and diseases. Here, we followed this
approach focusing on NMNAT2 levels, changes in NMN/NAD ratio and
protection conferred by WLDS expression and Sarm1 deletion. This is
the first demonstration of Wallerian pathway involvement at multiple
steps in a non-axotomy axonal stress.
A next crucial question is whether the activation of the Wallerian
pathway contributes to neurodegenerative disorders caused by mi-
tochondrial dysfunction. CCCP is widely used to impair mitochondrial
function and has proven instrumental for understanding the role of
Fig. 6. Highwire deficiency rescues loss of a subpopulation of dopaminergic (PPL1) neurons in Pink1 Drosophila mutants.
(A) Schematic image of a Drosophila brain with the PPL1 cluster of dopaminergic neurons shown in green (‘Created with BioRender’). (B) Representative images of
adult Drosophila (20 days old) brains stained with anti-TH antibody. The PPL1 cluster of dopaminergic neurons is shown. (C) Quantification of the number of
dopaminergic neurons per PPL1 cluster (Mean ± SEM; n = 16–25; one-way ANOVA followed by Tukey post-hoc test; **, p < 0.01). (D) Lifespan curves of wild-
type, HiwΔN, Pink1B9, HiwΔN Pink1B9 flies (n > 130 flies per condition; log-rank (Mantel-Cox) test. ****, p < 0.0001). (E,F) Analysis of climbing and flying ability of
7 days old flies of the indicated genotypes (Mean ± SEM; n = 3 climbing, n= 9 flying; one-way ANOVA followed by Tukey post-hoc test; NS, non-significant). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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mitochondria in a number of physiological and non-physiological cel-
lular processes. However, it remains unclear how much its potent and
acute mitochondrial toxicity reflects chronic mitochondrial dysfunction
in human pathologies. The strong protection achieved by blocking the
Wallerian pathway is remarkable, but the extent of mitochondrial da-
mage in neurodegenerative disorders is likely to be milder. The neu-
roprotection in vivo in Pink1 mutant flies represents a first indication of
the possible wider relevance of the Wallerian pathway to other mi-
tochondrial insults in vivo, although the use of alternative means to
impair mitochondria could provide further understanding of the me-
chanisms involved. The protection of neuronal soma in Pink1B9 flies
could be secondary to rescue of axon loss. However, knocking down
dNMNAT causes axon and cell body death (Neukomm et al., 2017). This
is likely because Drosophila only has one NMNAT isoform (compared to
three in mammals) and so a reduction in dNMNAT levels cause a more
profound damage to the whole cell, rather than predominantly affecting
axons (as it is the case with the major axonal isoform, NMNAT2, in
mammals). Finally, we cannot fully rule out the possibility that other
actions of Highwire contribute to these observations.
Among a number of neurodegenerative disorders associated with
mitochondrial dysfunction, the link between PD and axon loss is par-
ticularly important. PD involves preferential loss of substantia nigra
pars compacta dopaminergic neurons. These neurons have extremely
long and branched axons which are lost early in PD patients (Matsuda
et al., 2009; Tagliaferro and Burke, 2016), and, as such, may be more
vulnerable to axonal stresses. Wallerian-like degeneration has also been
implicated in other PD models, with WLDS protecting after MPTP and 6-
hydroxydopamine administration (Sajadi et al., 2004; Hasbani and
O'Malley, 2006; Cheng and Burke, 2010), and with neuroprotection in
Pink1 mutant flies by Highwire deficiency that can now be added to the
list. However, more comprehensive studies in genetic and chronic
models of PD in mammals will be needed to establish whether the
Wallerian pathway plays a causative role in PD pathology or simply
increases susceptibility to disease. Interestingly, we also show that
lower levels of NMNAT2 make neurites more vulnerable to the con-
sequences of CCCP-induced mitochondrial depolarisation and, as
NMNAT2 mRNA levels have been reported to vary hugely in the human
population (up to 50-fold differences) (Ali et al., 2016), some in-
dividuals might thus be at a much higher risk of mitochondrial dis-
orders.
5. Conclusions
We show that acute mitochondrial impairment induced by CCCP
leads to NMNAT2 depletion and subsequent activation of the Wallerian
pathway (Fig. 7), and that loss of dopaminergic neurons as a result of
mitochondrial dysfunction in flies with Pink1 loss-of-function mutation
can be prevented by modulation of the Wallerian pathway by Highwire
deletion. This study provides mechanistic insights on how mitochon-
drial dysfunction leads to axon degeneration and identifies the Wal-
lerian pathway as a potential contributor to axon pathology in mi-
tochondrial disorders. It is now important to test the role of the
pathway in models that more closely replicate human mitochondrial
diseases.
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